EHZF inhibitors are a class of chemical compounds that specifically target and inhibit the activity of the enhancer of zeste homolog (EZH), a protein that plays a crucial role in gene regulation through chromatin modification. EHZF, often referred to in the context of EHZF-like proteins, is involved in the regulation of gene expression by modulating the structure of chromatin, making certain regions of the DNA more or less accessible for transcription. This modulation is critical for various cellular processes, including differentiation, development, and the maintenance of cellular identity. EHZF inhibitors interfere with these processes by blocking the enzymatic activity of EHZF proteins, thereby preventing the addition of methyl groups to histone proteins, a key mechanism by which these proteins exert their regulatory functions.
Inhibitors of EHZF are valuable tools in research aimed at understanding the complex dynamics of epigenetic regulation. By selectively inhibiting EHZF activity, researchers can study the specific roles that these proteins play in chromatin remodeling and gene expression. This can help uncover how changes in chromatin structure influence cellular behavior and contribute to the regulation of various biological processes. Additionally, EHZF inhibitors can be used to explore the broader network of interactions within the cell that are influenced by chromatin state, providing insights into how epigenetic modifications are coordinated and maintained. These inhibitors are particularly useful in experiments designed to probe the mechanisms underlying gene silencing and activation, as well as in studies focused on the long-term stability of gene expression patterns across different cell types and developmental stages. Overall, EHZF inhibitors are powerful tools for advancing our understanding of epigenetics and the intricate molecular mechanisms that regulate gene expression in eukaryotic cells.
Items 1 to 10 of 14 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
1,10-Phenanthroline | 66-71-7 | sc-255888 sc-255888A | 2.5 g 5 g | $23.00 $32.00 | ||
1,10-Phenanthroline is a metal ion chelator that can sequester zinc ions and thus potentially interfere with the DNA binding activity of zinc finger proteins like ZNF281. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
5-Azacytidine is a DNA methyltransferase inhibitor that can alter gene expression. It might indirectly affect ZNF281 by modulating the transcriptional landscape. | ||||||
Mithramycin A | 18378-89-7 | sc-200909 | 1 mg | $55.00 | 6 | |
Mithramycin A is a DNA-binding antitumor antibiotic that inhibits SP1 transcription factor. As ZNF281 is also a transcription factor, there could be potential implications for its activity. | ||||||
Tamoxifen | 10540-29-1 | sc-208414 | 2.5 g | $272.00 | 18 | |
Tamoxifen is a selective estrogen receptor modulator (SERM) used in breast cancer treatment. Given the association of ZNF703 with breast cancer, tamoxifen may influence its expression. | ||||||
Letrozole | 112809-51-5 | sc-204791 sc-204791A | 25 mg 50 mg | $87.00 $147.00 | 5 | |
Letrozole, an aromatase inhibitor, might influence ZNF703 expression indirectly via estrogen modulation in breast cancer. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
As an HDAC inhibitor, trichostatin A can change chromatin structure and may influence ZNF703 transcription. | ||||||
Ribociclib | 1211441-98-3 | sc-507367 | 10 mg | $450.00 | ||
Another CDK4/6 inhibitor, ribociclib might indirectly modulate ZNF703 expression in specific cellular environments. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib, an EGFR inhibitor, affects multiple downstream signaling pathways and may have indirect effects on ZNF703 expression. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
As an inhibitor of HER2/neu and EGFR, lapatinib might indirectly influence ZNF703 expression in HER2+ breast cancers. | ||||||
Everolimus | 159351-69-6 | sc-218452 sc-218452A | 5 mg 50 mg | $131.00 $651.00 | 7 | |
By inhibiting mTOR, everolimus can influence various cellular processes, potentially affecting ZNF703 expression indirectly. | ||||||